NCT04574635 - Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2027

Conditions

Cervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedInfiltrating Cervical CarcinomaMetastatic Cervical CarcinomaRecurrent Cervical CarcinomaStage I Cervical Cancer FIGO 2018Stage IA Cervical Cancer FIGO 2018Stage IA1 Cervical Cancer FIGO 2018Stage IA2 Cervical Cancer FIGO 2018Stage IB Cervical Cancer FIGO 2018Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer FIGO 2018Stage IB3 Cervical Cancer FIGO 2018Stage II Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Stage IIA1 Cervical Cancer FIGO 2018Stage IIA2 Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018Stage III Cervical Cancer FIGO 2018Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Stage IIIC Cervical Cancer FIGO 2018Stage IIIC1 Cervical Cancer FIGO 2018Stage IIIC2 Cervical Cancer FIGO 2018Stage IV Cervical Cancer FIGO 2018Stage IVA Cervical Cancer FIGO 2018Stage IVB Cervical Cancer FIGO 2018

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

Trial Locations (2)

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic in Rochester, Rochester